Who are Raxtozinameran 6 months to 4 years of age's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comirnaty, Low Dose PF-07328948, Tozinameran 5 to 11 Years of age, BNT162b2, Famtozinameran 12 Years of age and older, Combination (Bivalent) BNT162b2 and BNT162b2 OMI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/raxtozinameran-6-months-to-4-years-of-age.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Raxtozinameran 6 months to 4 years of age — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Raxtozinameran 6 months to 4 years of age (raxtozinameran-6-months-to-4-years-of-age) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: viral entry inhibitor. Area: Infectious Disease.

marketed viral entry inhibitor SARS-CoV-2 virus Infectious Disease Live · refreshed every 30 min

Target snapshot

Raxtozinameran 6 months to 4 years of age (raxtozinameran-6-months-to-4-years-of-age) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Raxtozinameran 6 months to 4 years of age TARGET	raxtozinameran-6-months-to-4-years-of-age	Pfizer	marketed	viral entry inhibitor	SARS-CoV-2 virus
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Low Dose PF-07328948	low-dose-pf-07328948	Pfizer	marketed	small molecule	SARS-CoV-2 virus
Tozinameran 5 to 11 Years of age	tozinameran-5-to-11-years-of-age	Pfizer	marketed	vaccine	SARS-CoV-2 virus
BNT162b2	bnt162b2	Pfizer	marketed	vaccine	SARS-CoV-2 virus
Famtozinameran 12 Years of age and older	famtozinameran-12-years-of-age-and-older	Pfizer	marketed	monoclonal antibody	SARS-CoV-2 virus
Combination (Bivalent) BNT162b2 and BNT162b2 OMI	combination-bivalent-bnt162b2-and-bnt162b2-omi	Pfizer	marketed	vaccine	SARS-CoV-2 virus

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (viral entry inhibitor class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Raxtozinameran 6 months to 4 years of age — Competitive Intelligence Brief. https://druglandscape.com/ci/raxtozinameran-6-months-to-4-years-of-age. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab